Evogene Ltd. (TLV:EVGN)

Nuvei Statistics

Total Valuation

Evogene has a market cap or net worth of ILS 35.35 million. The enterprise value is 68.06 million.

Market Cap	35.35M
Enterprise Value	68.06M

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Evogene has 8.71 million shares outstanding. The number of shares has increased by 27.71% in one year.

Current Share Class	8.71M
Shares Outstanding	8.71M
Shares Change (YoY)	+27.71%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	0.99%
Owned by Institutions (%)	5.20%
Float	8.63M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.40
PB Ratio	0.77
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.20
EV / Sales	2.70
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.85

Financial Position

The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.21.

Current Ratio	1.06
Quick Ratio	0.84
Debt / Equity	0.21
Debt / EBITDA	n/a
Debt / FCF	-0.12
Interest Coverage	-63.07

Financial Efficiency

Return on equity (ROE) is -91.05% and return on invested capital (ROIC) is -68.80%.

Return on Equity (ROE)	-91.05%
Return on Assets (ROA)	-35.10%
Return on Invested Capital (ROIC)	-68.80%
Return on Capital Employed (ROCE)	-121.73%
Revenue Per Employee	215,295
Profits Per Employee	-484,023
Employee Count	117
Asset Turnover	0.17
Inventory Turnover	2.78

Taxes

In the past 12 months, Evogene has paid 33,512 in taxes.

Income Tax	33,512
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -76.14% in the last 52 weeks. The beta is 1.41, so Evogene's price volatility has been higher than the market average.

Beta (5Y)	1.41
52-Week Price Change	-76.14%
50-Day Moving Average	456.54
200-Day Moving Average	511.34
Relative Strength Index (RSI)	38.80
Average Volume (20 Days)	63,049

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Evogene had revenue of ILS 25.19 million and -56.63 million in losses. Loss per share was -9.24.

Revenue	25.19M
Gross Profit	10.34M
Operating Income	-84.78M
Pretax Income	-64.00M
Net Income	-56.63M
EBITDA	-78.77M
EBIT	-84.78M
Loss Per Share	-9.24

Balance Sheet

The company has 36.67 million in cash and 9.65 million in debt, giving a net cash position of 27.02 million or 3.10 per share.

Cash & Cash Equivalents	36.67M
Total Debt	9.65M
Net Cash	27.02M
Net Cash Per Share	3.10
Equity (Book Value)	46.15M
Book Value Per Share	-2.03
Working Capital	3.36M

Cash Flow

In the last 12 months, operating cash flow was -77.34 million and capital expenditures -2.26 million, giving a free cash flow of -79.60 million.

Operating Cash Flow	-77.34M
Capital Expenditures	-2.26M
Free Cash Flow	-79.60M
FCF Per Share	-9.14

Margins

Gross margin is 41.06%, with operating and profit margins of -336.57% and -224.82%.

Gross Margin	41.06%
Operating Margin	-336.57%
Pretax Margin	-254.09%
Profit Margin	-224.82%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-27.71%
Shareholder Yield	n/a
Earnings Yield	-160.18%
FCF Yield	-225.17%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 28, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	Jul 28, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

Evogene has an Altman Z-Score of -12.72. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-12.72
Piotroski F-Score	n/a